metformin has been researched along with canagliflozin in 78 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 58 (74.36) | 24.3611 |
| 2020's | 20 (25.64) | 2.80 |
| Authors | Studies |
|---|---|
| Aggarwal, N; Arbit, D; Canovatchel, W; Capuano, G; Polidori, D; Rosenstock, J; Usiskin, K; Zhao, Y | 1 |
| Capuano, G; Nicolle, LE; Usiskin, K; Ways, K | 1 |
| Canovatchel, W; Fu, M; Gross, JL; Guarisco, M; Kawaguchi, M; Meininger, G; Rosenstock, J; Schernthaner, G; Yee, J | 1 |
| Arias, P; Balis, DA; Canovatchel, W; Cefalu, WT; Leiter, LA; Meininger, G; Niskanen, L; Xie, J; Yoon, KH | 1 |
| Canovatchel, W; Davidson, J; Januszewicz, A; Lavalle-González, FJ; Meininger, G; Qiu, R; Tong, C | 1 |
| Black, S; Canovatchel, W; Charpentier, G; González-Gálvez, G; Hollander, P; Law, G; Mathieu, C; Meininger, G; Usiskin, K; Vercruysse, F; Wilding, JP | 1 |
| Capuano, G; Fung, A; Nicolle, LE; Usiskin, K | 1 |
| Seufert, J | 1 |
| Schnell, O | 1 |
| Bailey, RA; Blonde, L; Damaraju, CV; Martin, SC; Meininger, GE; Rupnow, MF | 1 |
| Forst, T; Goldenberg, R; Guthrie, R; Meininger, G; Stein, P; Vijapurkar, U; Yee, J | 1 |
| Ferrannini, E; Mari, A; Polidori, D | 1 |
| Farrell, K; Heise, T; Natarajan, J; Plum-Mörschel, L; Polidori, D; Rothenberg, P; Sha, S; Sica, D; Wang, SS | 1 |
| Dou, J; Lu, J; Zhang, Q | 1 |
| Artis, E; Berg, JK; Devineni, D; Morrow, L; Polidori, D; Rusch, S; Stein, P; Vaccaro, N | 1 |
| Dieu Van, NK; Han, P; Ji, L; Liu, Y; Meininger, G; Qiu, R; Vijapurkar, U; Yang, G | 1 |
| Arias, P; Balis, DA; Canovatchel, W; Langslet, G; Leiter, LA; Meininger, G; Millington, D; Vercruysse, F; Xie, J; Yoon, KH | 1 |
| Bode, B; Fung, A; Harris, S; Meininger, G; Stenlöf, K; Sullivan, D; Usiskin, K | 1 |
| Devineni, D; Murphy, J; Stieltjes, H; Wajs, E; Wang, SS | 1 |
| Rupprecht, H | 1 |
| Gupta, Y; Kalra, S | 1 |
| Cui, Y; Lu, M; Ma, L; Yang, T; Zhou, Y | 1 |
| Alba, M; Cerdas, S; Chacon, Mdel P; Eliaschewitz, FG; Lavalle-González, FJ; Tong, C | 1 |
| Capuano, G; Polidori, D; Qiu, R | 1 |
| Capuano, G; Chuck, L; Craig, J; González-Ortiz, M; Merton, K; Qiu, R; Rosenstock, J | 1 |
| Shyangdan, DS; Uthman, OA; Waugh, N | 1 |
| Blonde, L; Canovatchel, W; Fung, A; Meininger, G; Stenlöf, K; Xie, J | 1 |
| Ako, J; Anzai, T; Eguchi, K; Inoue, T; Kitakaze, M; Murohara, T; Node, K; Oyama, J; Saito, Y; Sakata, Y; Sata, M; Sato, Y; Shimizu, W; Suzuki, M; Taguchi, I; Tanaka, A; Tomiyama, H; Ueda, S; Uematsu, M; Watada, H; Yamashina, A | 1 |
| Aggarwal, N; Alba, M; Cao, A; Fung, A; Pfeifer, M; Rodbard, HW; Seufert, J | 1 |
| Adams, LA; Bedwell, DW; Calvert, NA; Cassidy, KC; Cramer, JW; Mohutsky, MA; Moulton, RD; Rougée, LR; Ruterbories, KJ; Yumibe, NP; Zhou, X | 1 |
| Canovatchel, W; Davidson, JA; Jodon, H; Lavalle-González, FJ; Qiu, R; Schernthaner, G; Vijapurkar, U | 1 |
| Bloch, MJ | 1 |
| Johansen, P; Neslusan, C; Sabapathy, S; Teschemaker, A; Willis, M; Yoong, K | 1 |
| Bailey, RA; Blonde, L; Meininger, G; Patel, CA; Vijapurkar, U | 1 |
| AlAzimi, SA; Arafa, NM; Marie, MA | 1 |
| Bobart, SA; Gleason, B; Martinez, N; Norris, K; Williams, SF | 1 |
| Andrews, TJ; Cox, RD; Kolb, J; Parker, C | 1 |
| Davidson, JA; Sloan, L | 1 |
| de Trixhe, XW; de Winter, W; Devineni, D; Dunne, A; Hsu, CH; Pinheiro, J; Polidori, D | 1 |
| Buchholt, AT; El Khoury, AC; Kamal, A; Schubert, A; Taieb, V | 1 |
| Lingvay, I | 1 |
| Drexler, A | 1 |
| Elshahed, MS; Lotfy, HM; Mohamed, D | 1 |
| Eisner, F; Eller, K; Eller, P; Lind, A; Mader, JK; Pieber, TR; Plank, J; Schilcher, G; Schwetz, V | 1 |
| Fixen, CW; Fixen, DR | 1 |
| Cuddihy, R; Davies, MJ; Garvey, WT; Leiter, LA; List, J; Ren, J; Van Gaal, L; Vijapurkar, U | 1 |
| Eckel, RH; Koh, KK; Lim, S | 1 |
| Garcia de Lucas, MD; Gómez Huelgas, R; Olalla Sierra, J; Pérez Belmonte, LM; Suárez Tembra, M | 1 |
| Fawzy, MG; Mahrouse, MA; Moussa, BA | 2 |
| Darwish, AM | 1 |
| Gupta, V; Johansen, P; Mane, A; Neslusan, C; Nilsson, A; Shah, M; Willis, M | 1 |
| Donnan, K; Segar, L | 1 |
| Asseburg, C; Neslusan, C; Willis, M | 1 |
| Barakat, GH; Elkady, EF; Hassib, ST; Taha, EA | 1 |
| de Campos, ML; Degaut, FLD; Dias, BCL; Fachi, MM; Peccinini, RG; Pontarolo, R | 1 |
| Druyts, E; Kanters, S; Lopes, S; Popoff, E; Sharma, R; Vrazic, H; Wilkinson, L | 1 |
| Shah, PA; Sharma, V; Shrivastav, PS; Yadav, MS | 1 |
| Scheen, AJ | 1 |
| Gujar, S; Mungantiwar, A; Pandita, N; Wattamwar, T | 1 |
| Fujisawa, Y; Fukami, M; Inoue, T; Kagami, M; Masunaga, Y; Muramatsu, M; Ogata, T; Ono, H; Saitsu, H | 1 |
| Aimalla, N; Amdur, RL; Awal, HB; Brichacek, B; Elzarki, A; Fakhri, M; Kundu, N; Nandula, SR; Sen, S | 1 |
| Doulla, M; Jetha, M; Shamchuk, A | 1 |
| Cai, M; Dilimulati, D; Gao, X; Qu, S; Shao, X; Xing, F; Zeng, Q; Zhang, M; Zhang, Y | 1 |
| Hao, Z; Li, G; Liu, Y; Shen, Y; Sun, Y; Wen, Y | 1 |
| Corremans, R; D'Haese, PC; De Broe, ME; Leysen, H; Maudsley, S; Neven, E; Verhulst, A; Vervaet, BA | 1 |
| Bech, PG; Fridhammar, A; Liu, A; Miresashvili, N; Nilsson, A; Stafford, S; Willis, M | 1 |
| Abdalsabour, S; Elnadi, S; Farouk, M; Trabik, YA | 1 |
| Phan, O; Pruijm, M; Zanchi, A | 1 |
| Cheng, X; He, B; Xing, C; Zhang, J | 1 |
| Angwin, CD; Britten, N; Hattersley, AT; Holman, R; Jones, AG; Pearson, ER; Sattar, N; Shepherd, MH; Shields, BM | 1 |
| Emam, AA; Emam, RA | 1 |
| Junsiritrakhoon, S; Osman, MA; Supharattanasitthi, W; Thanapairoje, K; Wichaiyo, S | 1 |
| Gustafson, KM; Kellon, EM | 1 |
| Corremans, R; D'Haese, PC; Dams, G; Verhulst, A; Vervaet, BA | 1 |
| Fawzy, MG; Said, MA | 1 |
| Li, G; Ni, J; Wang, S; Zhang, D | 1 |
| Chen, G; Chen, Y; He, Z; Huang, W; Li, D; Liu, C; Xiang, P; Yang, X; Yuan, L | 1 |
17 review(s) available for metformin and canagliflozin
| Article | Year |
|---|---|
[Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison beween canagliflozin and glimepiride].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endpoint Determination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intra-Abdominal Fat; Male; Metformin; Middle Aged; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiophenes | 2014 |
[Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison between canagliflozin and sitagliptin].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endpoint Determination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Randomized Controlled Trials as Topic; Sitagliptin Phosphate; Thiophenes; Triazoles; Young Adult | 2014 |
Combinational therapy with metformin and sodium-glucose cotransporter inhibitors in management of type 2 diabetes: systematic review and meta-analyses.
Topics: Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
[The role of SGLT-2 inhibitors in the treatment of type 2 diabetes].
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2015 |
Efficacy and tolerability of canagliflozin as add-on to metformin in the treatment of type 2 diabetes mellitus: a meta-analysis.
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.
Topics: Bayes Theorem; Benzhydryl Compounds; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Sorbitol; Weight Loss | 2016 |
Fixed-Dose Combination of Canagliflozin and Metformin for the Treatment of Type 2 Diabetes: An Overview.
Topics: Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glucosides; Humans; Hyperglycemia; Hypoglycemia; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
Topics: Bayes Theorem; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Metformin; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; United Arab Emirates | 2017 |
SODIUM GLUCOSE COTRANSPORTER 2 AND DIPEPTIDYL PEPTIDASE-4 INHIBITION: PROMISE OF A DYNAMIC DUO.
Topics: Adamantane; Benzhydryl Compounds; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Linagliptin; Metformin; Piperidines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Uracil | 2017 |
Managing and maintaining bone mineral density in diabetes patients with pharmacotherapy.
Topics: Bone Density; Canagliflozin; Diabetes Complications; Diabetes Mellitus; Fractures, Bone; Humans; Hypoglycemic Agents; Insulin; Metformin; Osteoporosis; Risk Factors; Thiazolidinediones | 2017 |
Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors.
Topics: Albuminuria; Atherosclerosis; Benzhydryl Compounds; Body Weight; Canagliflozin; Cardiovascular Diseases; Cardiovascular System; Glucagon; Glucagon-Like Peptides; Glucosides; Heart Failure; Hemodynamics; Humans; Hypoglycemic Agents; Ketones; Lipids; Liraglutide; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Osmosis; Risk Factors; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2018 |
SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes.
Topics: Acidosis, Lactic; Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Drug Therapy, Combination; Glucosides; Humans; Metformin; Risk; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Conducting and interpreting results of network meta-analyses in type 2 diabetes mellitus: A review of network meta-analyses that include sodium glucose co-transporter 2 inhibitors.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypoglycemic Agents; Metformin; Network Meta-Analysis; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Comparative efficacy of once-weekly semaglutide versus SGLT-2 inhibitors in patients inadequately controlled with one to two oral antidiabetic drugs: a systematic literature review and network meta-analysis.
Topics: Benzhydryl Compounds; Canagliflozin; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Glucosides; Humans; Hypoglycemic Agents; Metformin; Network Meta-Analysis; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2019 |
Insulin resistant diabetes mellitus in SHORT syndrome: case report and literature review.
Topics: Brazil; Canagliflozin; Child; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; Female; Growth Disorders; Human Growth Hormone; Humans; Hypercalcemia; Insulin Resistance; Metabolic Diseases; Metformin; Nephrocalcinosis; Puberty; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
Anti-ageing effects of FDA-approved medicines: a focused review.
Topics: Acarbose; Aging; Animals; Canagliflozin; Longevity; Male; Metformin; Quality of Life | 2023 |
Clinical Efficacy of Different Doses of Canagliflozin Combined with Metformin in the Treatment of Type 2 Diabetes: Meta-Analysis.
Topics: Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Treatment Outcome | 2023 |
30 trial(s) available for metformin and canagliflozin
| Article | Year |
|---|---|
Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Weight Loss; Young Adult | 2012 |
Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
Topics: Bacteriuria; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triazoles; Urinary Tract Infections | 2012 |
Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial.
Topics: Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiophenes; Treatment Outcome; Triazoles | 2013 |
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes; Treatment Outcome; Young Adult | 2013 |
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
Topics: Adolescent; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Thiophenes; Treatment Outcome; Triazoles | 2013 |
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin-Secreting Cells; Lipid Metabolism; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thiophenes; Treatment Outcome; Weight Loss; Young Adult | 2013 |
Urinary tract infection in randomized phase III studies of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Incidence; Male; Metformin; Middle Aged; Recurrence; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes; Urinary Tract Infections; Young Adult | 2014 |
Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin.
Topics: Aged; Blood Pressure; Body Mass Index; Canagliflozin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrazines; Quality Indicators, Health Care; Racial Groups; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Triazoles | 2014 |
Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
Topics: Blood Glucose; Blood Pressure; Canagliflozin; Candidiasis; Diabetes Mellitus, Type 2; Diuretics, Osmotic; Double-Blind Method; Drug Therapy, Combination; Female; Genital Diseases, Female; Genital Diseases, Male; Glucosides; Humans; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Pioglitazone; Pyrazines; Sitagliptin Phosphate; Thiazolidinediones; Thiophenes; Treatment Outcome; Triazoles; Weight Loss | 2014 |
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes.
Topics: Adult; Aged; Blood Glucose; C-Peptide; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Humans; Insulin-Secreting Cells; Least-Squares Analysis; Male; Metformin; Middle Aged; Pyrazines; Sitagliptin Phosphate; Sodium-Glucose Transporter 2; Sulfonylurea Compounds; Thiophenes; Time Factors; Triazoles | 2014 |
Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypertension; Hypoglycemic Agents; Kidney; Male; Metformin; Middle Aged; Plasma Volume; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes; Treatment Outcome; Water-Electrolyte Balance; Weight Loss | 2014 |
Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.
Topics: Blood Glucose; Canagliflozin; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Fasting; Female; Glucose; Glucosides; Humans; Kidney; Male; Metformin; Middle Aged; Postprandial Period; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Thiophenes | 2014 |
Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea.
Topics: Aged; Canagliflozin; China; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Glucosides; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Malaysia; Male; Membrane Transport Modulators; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiophenes; Vietnam | 2015 |
Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.
Topics: Blood Glucose; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glucosides; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds; Thiophenes; Time Factors; Treatment Outcome; Weight Loss | 2015 |
Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diuresis; Double-Blind Method; Fasting; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Mycoses; Osmolar Concentration; Thiophenes; Urinary Tract Infections | 2015 |
Effect of food on the pharmacokinetics of canagliflozin/metformin (150/1,000 mg) immediate-release fixed-dose combination tablet in healthy participants.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Canagliflozin; Cross-Over Studies; Drug Combinations; Fasting; Female; Food-Drug Interactions; Glucosides; Half-Life; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metabolic Clearance Rate; Metformin; Middle Aged; Postprandial Period; Tablets; Therapeutic Equivalency; Thiophenes; Young Adult | 2015 |
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypoglycemic Agents; Latin America; Male; Metformin; Middle Aged; Sitagliptin Phosphate; Sulfonylurea Compounds; Treatment Outcome | 2016 |
Apparent subadditivity of the efficacy of initial combination treatments for type 2 diabetes is largely explained by the impact of baseline HbA1c on efficacy.
Topics: Adult; Aged; Algorithms; Canagliflozin; Combined Modality Therapy; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Diet, Diabetic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Exercise; Female; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Biological; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Initial Combination Therapy With Canagliflozin Plus Metformin Versus Each Component as Monotherapy for Drug-Naïve Type 2 Diabetes.
Topics: Adult; Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Canagliflozin; Chronic Disease; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Failure; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality of Life; Sulfonylurea Compounds | 2016 |
Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.
Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Hypovolemia; Male; Metformin; Middle Aged; Mycoses; Reproductive Tract Infections; Sitagliptin Phosphate; Treatment Failure; Treatment Outcome; Urinary Tract Infections | 2016 |
Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Racial Groups; Sitagliptin Phosphate; Sulfonylurea Compounds; Weight Loss; Young Adult | 2016 |
Dynamic population pharmacokinetic-pharmacodynamic modelling and simulation supports similar efficacy in glycosylated haemoglobin response with once or twice-daily dosing of canagliflozin.
Topics: Adult; Aged; Aged, 80 and over; Canagliflozin; Diabetes Mellitus, Type 2; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Biological; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2017 |
Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes.
Topics: Adiponectin; Aged; Biomarkers; Blood Glucose; C-Reactive Protein; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Inflammation; Leptin; Male; Metformin; Middle Aged; Molybdoferredoxin; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Treatment Outcome; Tumor Necrosis Factor-alpha | 2018 |
Role of Canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes.
Topics: Adult; Aged; Antigens, CD34; Biomarkers; Blood Glucose; Canagliflozin; Cells, Cultured; Chemotaxis; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Endothelial Progenitor Cells; Exosomes; Female; Glycated Hemoglobin; Humans; Insulin; Male; Metformin; Middle Aged; Phenotype; Pilot Projects; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2021 |
Efficacy of canagliflozin versus metformin in women with polycystic ovary syndrome: A randomized, open-label, noninferiority trial.
Topics: Adolescent; Adult; Canagliflozin; China; Female; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Metformin; Middle Aged; Polycystic Ovary Syndrome; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Young Adult | 2022 |
Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting.
Topics: Canada; Canagliflozin; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Glucagon-Like Peptides; Humans; Hypoglycemic Agents; Metformin; Quality-Adjusted Life Years | 2022 |
Canagliflozin combined with metformin versus metformin monotherapy for endocrine and metabolic profiles in overweight and obese women with polycystic ovary syndrome: A single-center, open-labeled prospective randomized controlled trial.
Topics: Adolescent; Adult; Blood Glucose; Canagliflozin; Female; Humans; Insulin; Insulin Resistance; Metabolome; Metformin; Obesity; Overweight; Polycystic Ovary Syndrome; Prospective Studies; Young Adult | 2022 |
Patient preference for second- and third-line therapies in type 2 diabetes: a prespecified secondary endpoint of the TriMaster study.
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Patient Preference; Pioglitazone; Sitagliptin Phosphate; Treatment Outcome | 2023 |
Remission effect of Canagliflozin in patients with newly diagnosed type 2 diabetes mellitus: a protocol for a multicenter, parallel-group, randomized, controlled, open-label trial.
Topics: Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2023 |
31 other study(ies) available for metformin and canagliflozin
| Article | Year |
|---|---|
Oral combination therapy in primary care.
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Drug Therapy, Combination; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Metformin; Pioglitazone; Primary Health Care; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Thiazolidinediones | 2015 |
Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks.
Topics: Adiposity; Aged; Body Composition; Body Mass Index; Body Weight; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Time Factors; Waist Circumference; Weight Loss | 2016 |
Difference in the Pharmacokinetics and Hepatic Metabolism of Antidiabetic Drugs in Zucker Diabetic Fatty and Sprague-Dawley Rats.
Topics: Administration, Intravenous; Animals; Biotransformation; Canagliflozin; Chromans; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Glucuronosyltransferase; Glyburide; Hepatocytes; Humans; Hypoglycemic Agents; Liver; Male; Metformin; Rats, Sprague-Dawley; Rats, Zucker; Rosiglitazone; Species Specificity; Substrate Specificity; Sulfotransferases; Thiazolidinediones; Troglitazone | 2016 |
Blood pressure effects of SGLT2 inhibitors make them an attractive option in diabetic patients with hypertension.
Topics: Antihypertensive Agents; Benzhydryl Compounds; Blood Pressure; Blood Pressure Determination; Canagliflozin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Glucosides; Humans; Hypertension; Hypoglycemic Agents; Metformin; Off-Label Use; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Cost-effectiveness of Canagliflozin versus Sitagliptin When Added to Metformin and Sulfonylurea in Type 2 Diabetes in Canada.
Topics: Aged; Blood Glucose; Canada; Canagliflozin; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Models, Econometric; Quality-Adjusted Life Years; Sitagliptin Phosphate; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds | 2016 |
A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures.
Topics: Aged; Blood Glucose; Blood Pressure Determination; Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemia; Hypoglycemic Agents; Male; Metformin; Middle Aged; Quality Indicators, Health Care; Randomized Controlled Trials as Topic; Sulfonylurea Compounds; Thiophenes; Treatment Outcome | 2016 |
Effect of canagliflozin and metformin on cortical neurotransmitters in a diabetic rat model.
Topics: Acetylcholinesterase; Amino Acids; Animals; Biogenic Monoamines; Blood Glucose; Canagliflozin; Cerebral Cortex; Diabetes Mellitus, Experimental; Disease Models, Animal; Glycosuria; Male; Metformin; Neurotransmitter Agents; Rats, Wistar | 2016 |
Euglycemic Ketoacidosis Caused by Sodium-Glucose Cotransporter 2 Inhibitors: A Case Report.
Topics: Adult; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Ketosis; Liraglutide; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2016 |
Euglycemic Diabetic Ketoacidosis with Elevated Acetone in a Patient Taking a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor.
Topics: Acetone; Antihypertensive Agents; Blood Glucose; Canagliflozin; Diabetes Complications; Diabetic Ketoacidosis; Female; Humans; Insulin; Metformin; Middle Aged; Sodium-Glucose Transporter 2 | 2017 |
Can we go beyond surrogates?
Topics: Benzhydryl Compounds; Canagliflozin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Glucosides; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Different mathematical processing of absorption, ratio and derivative spectra for quantification of mixtures containing minor component: An application to the analysis of the recently co-formulated antidiabetic drugs; canagliflozin and metformin.
Topics: Canagliflozin; Drug Compounding; Hypoglycemic Agents; Limit of Detection; Metformin; Models, Theoretical; Reproducibility of Results; Solutions; Spectrophotometry | 2018 |
Combined metformin-associated lactic acidosis and euglycemic ketoacidosis.
Topics: Acidosis, Lactic; Aged; Blood Glucose; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Gluconeogenesis; Humans; Insulin; Ketosis; Kidney Failure, Chronic; Liraglutide; Male; Metformin | 2017 |
Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study.
Topics: Aged; Blood Glucose; Blood Pressure; Body Weight; Canagliflozin; Diabetes Mellitus, Type 2; Female; Gliclazide; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Retrospective Studies; Sitagliptin Phosphate | 2018 |
Different resolution techniques for management of overlapped spectra: Application for the determination of novel co-formulated hypoglycemic drugs in their combined pharmaceutical dosage form.
Topics: Benzhydryl Compounds; Canagliflozin; Drug Combinations; Glucosides; Hypoglycemic Agents; Limit of Detection; Linagliptin; Linear Models; Metformin; Reproducibility of Results; Spectrophotometry, Ultraviolet; Tablets | 2018 |
Metabolic Acidosis in Postsurgical Patient on Canagliflozin and Metformin: A Case Report.
Topics: Acidosis; Adult; Canagliflozin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Ketosis; Male; Metformin; Middle Aged; Postoperative Complications; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Long-Term Clinical Benefits of Canagliflozin 100 mg Versus Sulfonylurea in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin in India.
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; India; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Sulfonylurea Compounds; Treatment Outcome | 2019 |
Validated Liquid Chromatographic Method for the Determination of (Canagliflozin, Dapagliflozin or Empagliflozin) and Metformin in the Presence of (1-Cyanoguanidine).
Topics: Benzhydryl Compounds; Canagliflozin; Chromatography, High Pressure Liquid; Glucosides; Guanidines; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
A new HPLC-MS/MS method for the simultaneous quantification of SGLT2 inhibitors and metformin in plasma and its application to a pharmacokinetic study in healthy volunteers.
Topics: Benzhydryl Compounds; Canagliflozin; Chromatography, High Pressure Liquid; Glucosides; Humans; Linear Models; Metformin; Reproducibility of Results; Sensitivity and Specificity; Sodium-Glucose Transporter 2 Inhibitors; Tandem Mass Spectrometry | 2019 |
Challenges in simultaneous extraction and chromatographic separation of metformin and three SGLT-2 inhibitors in human plasma using LC-MS/MS.
Topics: Benzhydryl Compounds; Calibration; Canagliflozin; Chromatography, Liquid; Glucosides; Humans; Limit of Detection; Metformin; Plasma; Reproducibility of Results; Sodium-Glucose Transporter 2 Inhibitors; Solid Phase Extraction; Tandem Mass Spectrometry | 2019 |
SGLT2 inhibitor or GLP-1 receptor agonist in type 2 diabetes?
Topics: Canagliflozin; Diabetes Mellitus, Type 2; Double-Blind Method; Glucagon-Like Peptide-1 Receptor; Glucagon-Like Peptides; Humans; Metformin; Sodium-Glucose Transporter 2 | 2019 |
Development of LC-MS/MS method for simultaneous determination of Canagliflozin and Metformin in human plasma and its pharmacokinetic application in Indian population under fast and fed conditions.
Topics: Administration, Oral; Adult; Canagliflozin; Chromatography, High Pressure Liquid; Drug Combinations; Fasting; Humans; India; Linear Models; Male; Metformin; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2020 |
Application of experimental design in HPLC method optimization and robustness for the simultaneous determination of canagliflozin, empagliflozin, linagliptin, and metformin in tablet.
Topics: Benzhydryl Compounds; Canagliflozin; Chromatography, High Pressure Liquid; Dipeptidyl-Peptidase IV Inhibitors; Glucosides; Limit of Detection; Linagliptin; Linear Models; Metformin; Reproducibility of Results; Research Design; Sodium-Glucose Transporter 2 Inhibitors; Tablets | 2021 |
Possible association between diabetic ketoacidosis and use of sodium-glucose co-transporter 2 inhibitor in a 17-year-old youth with type 2 diabetes.
Topics: Adolescent; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2021 |
Effects of canagliflozin and metformin on insulin resistance and visceral adipose tissue in people with newly-diagnosed type 2 diabetes.
Topics: Biomarkers; Canagliflozin; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Intra-Abdominal Fat; Male; Metformin; Middle Aged; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Progression of established non-diabetic chronic kidney disease is halted by metformin treatment in rats.
Topics: Adenine; Animals; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Humans; Male; Metformin; Proteomics; Rats; Renal Insufficiency, Chronic | 2022 |
Fourier Transform Infrared Spectroscopic, Spectrofluorimetric Assays of Canagliflozin, and Stability-Indicating UV-Spectrophotometric Method for the Simultaneous Determination of Canagliflozin and Metformin.
Topics: Canagliflozin; Fourier Analysis; Metformin; Solvents; Spectrometry, Fluorescence; Spectroscopy, Fourier Transform Infrared | 2022 |
Metformin versus SGLT-2 inhibitors: how low can we go?
Topics: Animals; Canagliflozin; Female; Humans; Hypoglycemic Agents; Male; Metformin; Rats; Renal Insufficiency, Chronic; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Ecofriendly appraisal of stability-indicating high-performance chromatographic assay of canagliflozin and metformin with their toxic impurities; in silico toxicity prediction.
Topics: Canagliflozin; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Hypoglycemic Agents; Metformin; Reproducibility of Results | 2023 |
Hypertriglyceridemia in equines with refractory hyperinsulinemia treated with SGLT2 inhibitors.
Topics: Animals; Canagliflozin; Diabetes Mellitus, Type 2; Glucose; Glucosides; Horse Diseases; Horses; Hyperinsulinism; Hyperlipidemias; Hypertriglyceridemia; Hypoglycemic Agents; Male; Metformin; Sodium-Glucose Transporter 2 Inhibitors | 2023 |
Metformin and Canagliflozin Are Equally Renoprotective in Diabetic Kidney Disease but Have No Synergistic Effect.
Topics: Animals; Canagliflozin; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hyperglycemia; Kidney; Male; Metformin; NF-kappa B; Quercetin; Rats; Rats, Wistar | 2023 |
Valuation of environmental influence of recently invented high-performance liquid chromatographic method for hypoglycemic mixtures of gliflozins and metformin in the presence of melamine impurities: Application of molecular modeling simulation approach.
Topics: Canagliflozin; Chromatography, High Pressure Liquid; Hypoglycemic Agents; Metformin; Sodium-Glucose Transporter 2 Inhibitors; Tablets | 2023 |